4
Participants
Start Date
December 18, 2020
Primary Completion Date
September 17, 2021
Study Completion Date
September 17, 2021
Sulfur hexafluoride lipid-type A microspheres
Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
The Children's Hospital of Philadelphia, Philadelphia
Children's Hospital of Philadelphia
OTHER